【基石药业-B(02616.HK):舒格利单抗GEMSTONE-302长期生存数据再登《柳叶刀•肿瘤学》】智通财经APP

智通财经
Yesterday
【基石药业-B(02616.HK):舒格利单抗GEMSTONE-302长期生存数据再登《柳叶刀•肿瘤学》】智通财经APP讯,基石药业-B(02616.HK)发布公告,舒格利单抗联合含铂化疗一线治疗鳞状和非鳞状IV期非小细胞肺癌(NSCLC)(非致癌基因驱动型)的III期临床研究(GEMSTONE-302)长期生存数据,发表于国际顶级综合性医学期刊《柳叶刀•肿瘤学》(The Lancet Oncology)。继该研究的无进展生存期(PFS)最终分析和总生存期(OS)期中分析结果先后发表于《柳叶刀•肿瘤学》(2022年)与《自然•癌症》(Nature Cancer,2023年)后,此次凭借长期生存数据再度登陆同一顶级期刊,实现了舒格利单抗获益证据链的完整构建,进一步彰显其临床价值,并巩固了其在中国及欧洲地区晚期NSCLC治疗领域的标准一线治疗地位。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10